AKT2 and melanoma: The splicing factor hnRNPK drives a splicing switch of AKT2 (isoform 210 to 206), restoring kinase hyperactivity via retention of the A-loop fragment and conferring MAPK-targeted therapy resistance in melanoma through PI3K-AKT pathway activation.